Brief: Allena Pharma Announces Streamlined Design For Urirox-2, Second Pivotal Clinical Trial Of Reloxaliase For Enteric Hyperoxaluria
12/02/2020 12:18
Feb 12 (Reuters) - Allena Pharmaceuticals Inc ALNA.O :
* ALLENA PHARMACEUTICALS ANNOUNCES STREAMLINED DESIGN FOR
URIROX-2, SECOND PIVOTAL CLINICAL TRIAL OF RELOXALIASE FOR
ENTERIC HYPEROXALURIA
* ALLENA PHARMACEUTICALS - PLANS TO SUBMIT A PROTOCOL
AMENDMENT
AND ASSOCIATED STUDY DOCUMENTS FOR REVISED TRIAL DESIGN IN Q1 OF
2020 FOR URIROX-2
* ALLENA PHARMACEUTICALS INC - INTERIM ANALYSIS IS PROJECTED
FOR
Q3 OF 2021 FOR URIROX-2
Source text for Eikon: ID:nGNX1D7b6t
Further company coverage: ALNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allena Pharmaceuticals
See all newsBrief: Allena Pharmaceuticals Inc - On September 6, Received Notice From Nasdaq That Its Shares Will Be Suspended At Open Of Business On September 8, 2022
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
U.S. STOCKS ON THE MOVE-ChannelAdvisor, HyreCar, ADT, miners
U.S. STOCKS ON THE MOVE-Timken, Bed Bath & Beyond, HyreCar, chip stocks
Allena down on bankruptcy filing